FreeMind Investments

FreeMind Investments is a venture capital firm dedicated to advancing the life sciences industry through strategic R&D investments. The firm focuses on companies across all stages of development, with a particular emphasis on pre-clinical and clinical stage programs, aiming to bridge the critical "biotech startup valley of death." They invest in solutions addressing human health conditions, including therapeutics and medical devices.

FreeMind Investments was launched in 2021 as a venture capital fund, a partnership between the FreeMind Group and Daewoong Pharmaceutical Co., Ltd. The FreeMind Group, founded in 1999, is a leading consultancy specializing in securing non-dilutive funding for life science organizations. This unique foundation allows FreeMind Investments to leverage an exclusive dataset, extensive life science managerial experience, and a proven track record in investments, combining strengths to make impactful investments.

The firm employs a data-driven investment model, utilizing a proprietary de-risking formula that identifies potential scientific and business success. This formula incorporates an organizational quality score from FreeMind Group's analysis, rigorous scientific due diligence by leading key opinion leaders, and a detailed assessment of business potential. Beyond direct equity investments, FreeMind Investments offers its portfolio companies valuable pharma deal-making opportunities, including access to the Asian market, co-development initiatives, and strategic partnerships.

The team at FreeMind Investments comprises experienced life science executives, including Founder & Managing Partner Ram May-Ron, who also leads FreeMind Group, and Co-Founder & Venture Partner B. Christopher Kim, with extensive experience in life sciences VC and big pharma. The firm's portfolio includes companies like Vincere Biosciences, Abalone Bio, and General Proximity, focusing on areas such as drug discovery and induced proximity medicines.